Lupus Nephritis

Phase 2 TULIP-LN Trial: Anifrolumab shows efficacy in treating lupus nephritis

The Phase 2 randomized, double-blind TULIP-LN trial evaluating the safety and efficacy of anifrolumab in treating active lupus nephritis (LN) has shown promising results through the second year of the study, according to a study. Patients received intravenous anifrolumab doses, with the initial 3 doses at 900 mg followed by...